
The aim of this study is to compare outcomes in adults with type 2 diabetes (T2D) suboptimally controlled with basal insulin who initiated treatment with iGlarLixi or premixed insulin. This retrospective real‐world analysis was conducted using data from adults (≥18y) with T2D in the US Optum Clinformatics database who had previously received basal insulin and newly initiated iGlarLixi or premixed insulin. In this observational study in people with suboptimally controlled T2D with basal insulin, once daily iGlarLixi was an effective alternative to premixed insulin with significantly higher treatment persistence, similar adherence and HbA1c reduction, and numerically lower hypoglycemia events, HRU, and costs, regardless of age or baseline HbA1c.
Like
Save
Share